We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Brand drugmaker Advancis Pharmaceutical and generic firm Par Pharmaceutical last week finalized an agreement to develop and co-promote a new brand version of the widely used generic antibiotic amoxicillin.
Even though it supports HHS' goal of conducting comparative research on health outcomes, PhRMA maintains that research limited to prescription drugs, and then only to comparative effectiveness analysis, is not an effective approach toward achieving the goal of improved quality, effectiveness and efficiency.
An aging population and increasing healthcare awareness worldwide are drivers that will push the global pharmaceutical market past $900 billion in 2008, according to a new report by a market analysis firm.
The Centers for Medicare & Medicaid Services (CMS) has created a new code for hospitals to use when billing Medicare for approved drugs that have not yet been assigned billing codes nor determined to be eligible for special pass-through payments as new products.
While supporting HHS' goal of conducting comparative research on health outcomes, PhRMA contends research limited only to prescription drugs, and then only to comparative effectiveness analysis, is not an effective approach toward achieving the goal of improved quality, effectiveness and efficiency.
Despite strong gains by generic firms in bringing products to market, brand firms may still have an advantage over generic rivals on products used to treat severe illnesses, according to a new survey on consumer attitudes toward generic drugs.
Abbott Laboratories recently squared off with AIDS activists who want the government to break the patent on Abbott’s AIDS drug Norvir (ritonavir) and allow generic versions of the product. The controversy stems from Abbott’s decision in December to raise the price of Norvir by 400 percent — a move that Abbott argues reflects market value of the product.
Ivax Pharmaceuticals has received the green light from Polish antitrust authorities to acquire a controlling interest in the Polish generic firm Kutnowskie Zaklady Farmaceutyczne Polfa (Polfa Kutno) — a move that follows other recent international acquisitions in the generic industry.
A U.S. Senator is expected to introduce legislation this month that would compel pharmaceutical benefit managers (PBMs) to report details about their financial arrangements with drugmakers.
The arrival of generic biologics should not be seen as a threat to the biotechnology industry, according to industry analyst cited in a new study that paints a rosy picture of biotech’s future.